Richiedi una copia del documento: Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: Insights from the HORIZONS-AMI trial

Captcha code
Annulla